Current data indicate that evaluating T and B cell densities in CRC tumors exhibits higher accuracy than evaluating PD-L1 expression in predicting the effectiveness of immunotherapy (12), because PD-L1 can be heterogeneously expressed within diverse regions of a tumor (12). The gene discussed is CD274; the disease is neoplasm.